A technology foundation and legacy built through years of visual neuroprosthetics work
Cortigent’s work builds on years of experience developing implantable visual neuroprosthetics, including Argus II and the Orion Early Feasibility Study.
Technology timeline
From retinal stimulation to cortical neurostimulation
Second Sight Medical Products
Development of implantable visual neuroprosthetic systems, wireless communication and patient-fitting methods.
Argus II commercial experience
With more than 350 implants, Argus II was an FDA-approved retinal prosthesis marketed from 2011 to 2019. Although no longer commercially available, the experience gained through its development helped shape Cortigent’s current platform.
Orion Early Feasibility Study
The electrode array moved from the retina to the visual cortex to investigate artificial vision through precise cortical stimulation.
One platform, two programs
Precision neurostimulation for artificial vision and recovery of upper-limb function following stroke.
Legacy contribution
Experience informing the current platform
Historical video
Historical patient stories, presented in context
These Argus II patient stories illustrate the human impact of Cortigent’s historical visual-neuroprosthetics work. They do not depict Orion.
Argus II was implanted in more than 350 patients and marketed from 2011 to 2019 and is no longer commercially available.
German Argus II patient stories
German patients share their experiences with the Argus II retinal prosthesis.
Experience carried forward into today’s programs
Cortigent is applying this foundation to two current programs built on its cortical-surface platform.
